DIRS.INFO The most relevant business & tech news

☆ S&P on pace to score fourth month of consecutive gains. History tells us what could come next
▼ + stars: | 2024-02-29 | by ( Bob Pisani | ) www.cnbc.com time to read: +3 min

The S & P 500 is ending February with a gain of almost 5%. S & P 500: Four big months November: up 8.9% December: up 4.4% January: up 1.6% February: up 4.6% The November gain of 8.9% was one of the 20 best monthly performances in history. The S & P has advanced about 5% since passing the old January 2022 historic high, which it crossed on Jan. 19, this year. Put another way: the S & P has recovered all the bear market losses from the old high in January 2022 to the bear market bottom in October 2022, and added another 5%. "Yet it also offers encouragement that no post-recovery selloff saw the start of a new bear market before rebounding and proceeding onto additional new highs."

Persons: Steve Starker, Todd Sohn, Eli Lilly, Nicholas Colas, Sam Stovall Organizations: Nvidia, P, Technology, Services, Care, Broadcom, Communication Services, Meta, Health Care, Merck, Depot, Costco, JPMorgan, Mastercard, Berkshire Hathaway, Research Locations: BTIG

☆ Watch out: These stocks are too expensive as the market trades near record highs
▼ + stars: | 2024-02-28 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

It could be time to take some profits with stocks near record highs. But that same hot streak is making some stocks look expensive. Wall Street's biggest artificial intelligence darling surfaced on the screen for most expensive stocks. But the company's trailing 12-month P/E ratio (P/E TTM) of 65.5 suggests the stock is overvalued, especially when compared to its historical earnings. But Eli Lilly's P/E ratio on a trailing 12-month basis of 130.5 shows the stock is expensive.

Persons: Eli Lilly, Eli Lilly's Organizations: Dow Jones, CNBC, Stock, Nvidia, Merck

☆ Jim Cramer says stay clear of this retail stock: 'It is not something you want to own'
▼ + stars: | 2024-02-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

First Solar : Shares rose more than 3% after the solar firm's quarterly earnings topped estimates, and its guidance was formidable. Urban Outfitters : Shares fell 13% after earnings, revenue and same-store sales growth missed Wall Street's expectations. While Cramer complimented the performance of its clothing-rental business, Nuuly, he said investors should not view Urban Outfitters as much more than an industry temperature check. That seems like good news for GE Healthcare , according to Cramer, whose Charitable Trust also owns shares of the medical-equipment maker. GE Healthcare has been the best-performing health-care stock in the S & P 500 in February, "and it's not done," Cramer said.

Persons: Jim Cramer's, Cramer, Eli Lilly Organizations: CNBC, Club, Novo Nordisk, Charitable Trust, Universal Health Services, GE Healthcare, Trust

☆ The pet drugs vets are now prescribing look a lot more like human medications
▼ + stars: | 2024-02-28 | by ( Ian Thomas | ) www.cnbc.com time to read: +7 min

If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don't need to look much further than weight loss drugs. When Pfizer spun off its animal health business in 2013 creating Zoetis, about 65% of the company's business was livestock-related. That has flipped now, with 64% of the company's revenue coming from products for companion animals like cats and dogs. Peck credits the Pfizer spinoff for allowing Zoetis to better balance what the company wanted to do in animal health versus the human health side. A similar product was approved for cats, marking the first time that monoclonal antibody treatments, which have become increasingly popular for treating human illnesses, have been used to treat pet osteoarthritis pain.

Persons: Kristin Peck, Eli Lilly, Peck, Zoetis, We've, it's, We'll Organizations: CNBC, Novo Nordisk, Pfizer, AstraZeneca, FDA

☆ Cramer gives the portfolio's core holdings a makeover — 4 are booted, 6 are added including a trio of tech giants
▼ + stars: | 2024-02-28 | by ( Morgan Chittum | ) www.cnbc.com time to read: +12 min

COST 5Y mountain Costco's stock performance over the past five years. DHR 5Y mountain Danaher's stock performance over the past five years. ETN 5Y mountain Eaton Corp.'s stock performance over the past five years. "The megatrends are real serious, and [Eaton] is a real serious company," Jim said. TJX 5Y mountain TJX Companies' stock performance over the past five years.

Persons: Jim Cramer, Jeff Marks, Morgan Stanley, Wall, Beijing's, Jim, Eaton, Linde, Lilly's, Eli Lilly, We've, Zepbound, Mark Zuckerberg's, Mark Zuckerberg, OpenAI, Copilot, management's, Nvidia, TJ Maxx, TikTok, Gen Zers, TJX, Jim Cramer's, Satya Narayana Nadella, Lucas Jackson Organizations: GE Healthcare, Meta, Microsoft, Johnson, Natural Resources, Starbucks, Apple, Apple Music, Services, Amazon, Amazon Web Services, Prime, Costco, Danaher, Eaton Corp, Investors, GE, LIN, Novo Nordisk's Wegovy, Novo Nordisk, Management, Nvidia, TJX Companies, Marshalls, CNBC Locations: Eaton, China, Manhattan, New York City

☆ Viking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.
▼ + stars: | 2024-02-28 | by ( ) www.businessinsider.com time to read: +3 min

Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.

Persons: —, Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California

☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
▼ + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.

Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina

☆ One down one to go — what we learned from TJX's great quarter and hope to hear from Salesforce
▼ + stars: | 2024-02-28 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Eli Lilly shares fell 1% on Wednesday following a similar drop in the prior session. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Salesforce, Jim, Let's, Eli Lilly, Jim Cramer's Organizations: CNBC, TJX Companies, Management, Therapeutics Locations: GLP

☆ CNBC Changemakers: Fortune 500 CEOs, Naomi Osaka and Alex Cooper share a success secret
▼ + stars: | 2024-02-28 | by ( Julia Boorstin | ) www.cnbc.com time to read: +5 min

Leading the way are health care, with 22%; tech, with 14%; and consumer products and financial services, tied at 10%. Kate Ryder is closing major gaps in women's and family health care with Maven. Michelle Zatlyn, co-founder and chief operating officer at Cloudflare, is giving companies AI tools to bolster cybersecurity and lower costs for vulnerable, critical infrastructure providers, including schools and local election systems. The Changemakers serve as a reminder that success is a result of leading in ways that are authentic. In the book she explored the concept of "reformers" — women working to fix broken systems.

Persons: Anat Ashkenazi, Eli Lilly, Svanika Balasubramanian, Bobbie, Laura Modi, Baby2Baby, Norah Weinstein, Kelly Sawyer Patricof, Alex Cooper, Tracee Ellis Ross, Naomi Osaka, Balasubramanian, Jessica Chang, Maayan Cohen, Kate Ryder, Maven, Monique Rodriguez, Jessica Berman, Kathy Hannun, Clara Shih, Michelle Zatlyn, Kristin Peck, Julia Boorstin Organizations: CNBC, U.S, RePurpose Global, rePurpose, Women's Soccer League, Dandelion Energy, cybersecurity Locations: Changemakers, Cloudflare

☆ Cramer says the price target bump for this stock ahead of its earnings is a 'red flag'
▼ + stars: | 2024-02-27 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. But Jim Cramer said the biggest theme in the market right now is cybersecurity. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Jim, Eli Lilly, Jim assuaged, it's, Wells Fargo, Jim Cramer's Organizations: CNBC, Palo Alto Networks, Viking Therapeutics

☆ Viking Therapeutics stock jumps 80% after positive weight loss drug trial results
▼ + stars: | 2024-02-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company's experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade. Separately, the company said it expects to release early-stage trial data on an oral version of its weight loss drug. Viking Therapeutics' drug targets GLP-1 and another hormone called GIP. Those are the same hormones that Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, target.

Persons: Brian Lian, Eli Lilly's Organizations: Viking Therapeutics, Viking, Food and Drug Administration

☆ Drugs like Ozempic and Wegovy could strengthen the US economy, Goldman Sachs predicts
▼ + stars: | 2024-02-27 | by ( Bryan Mena | ) edition.cnn.com time to read: +4 min

Washington, DC CNN —The US economy is set to reap considerable benefits from Americans taking popular medications used for weight loss, including Ozempic and Wegovy, Goldman Sachs analysts wrote in a recent research report. Originally developed to treat type 2 diabetes, they proved to be highly effective at helping people shed weight in clinical trials. (Ozempic has not been approved for weight loss by regulators, though Wegovy, a similar drug, has.) Goldman Sachs argues that since poor health unambiguously weighs on the economy, improving health outcomes due to GLP-1s could lower costs and boost productivity, shoring up economic output. For some Americans who are obese but don’t have diabetes, obtaining those drugs has become difficult, if not impossible.

Persons: Goldman Sachs, Eli Lilly, Jody Dushay, Beth, Doug Langa, they’ve Organizations: DC CNN, Government, Novo Nordisk, Beth Israel Deaconess Medical, CNN Locations: Washington, United States, North America, Novo

☆ Jim Cramer: Viking Therapeutics' weight-loss data not enough to dethrone Eli Lilly in GLP-1s
▼ + stars: | 2024-02-27 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday downplayed the competitive risk to Eli Lilly — a longtime holding in his Charitable Trust — presented by Viking Therapeutics ' new weight-loss drug data. Currently, Eli Lilly and Wegovy maker Novo Nordisk are the dominant players in the GLP-1 category. Eli Lilly and Novo Nordisk are far larger, worth around $733 billion and $550 billion as of Tuesday. Eli Lilly shares, among the best performers in the S & P 500 this year, fell slightly Tuesday. Cramer's Charitable Trust, the portfolio used by the CNBC Investing Club , has long owned Eli Lilly.

Persons: CNBC's Jim Cramer, Eli Lilly —, —, Eli Lilly, Cramer, Eli Lilly's tirzepatide, David Ricks, Lilly's, retatrutide Organizations: Viking Therapeutics, Novo Nordisk, Viking, Leerink Partners, Charitable Trust, CNBC Locations: Lilly

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

Berenberg increased its price target on Eli Lilly on the back of expected strong sales of its weight loss drug, Zepbound. The firm kept its $21 price target, saying shares are "ready to inflect" with hardware cost deflation and investment tax credit boosting growth. Danely's $820 price target on the buy-rated blockbuster chipmaker suggests 3.6% potential upside for shares since Monday's close. — Pia Singh 5:38 a.m.: Berenberg hikes Eli Lilly price target Eli Lilly has been on a tear this year, and Berenberg expects even more gains from here. Analyst Kerry Holford reiterated his buy rating on the stock and raised his price target to $850 from $680.

Persons: Berenberg, Eli Lilly, John Hodulik, Hodulik, — Pia Singh, Wells, Steven Cahall, Cahall, ROKU, Fred Imbert, BofA Evercore, James West, Christopher Danely, Danely, Goldman Sachs, Edward Jones, James Shanahan, Goldman, Marcus, Apiro Dounls, Sunoco, Kerry Holford, Holford, Zepbound Organizations: CNBC, pharma, Nvidia, Citi, Sunoco, NuStar Energy, Netflix, UBS, Vizio, CTV, ISI, BofA, BofA Evercore ISI, Bank of America, Micron Technology, NuStar, SUN Locations: Wells, Sunrun, Monday's

☆ Here are Tuesday's biggest analyst calls: Nvidia, Arm, Tesla, Rivian, Netflix, Micron, Roku, Seagate & more
▼ + stars: | 2024-02-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Citi reiterates Snowflake as a top pick Citi said Snowflake remains a top pick at the firm. Citi reiterates Micron as buy Citi said concerns about the stock underperformance is overdone and investors should buy the dip in top pick Micron. "We reiterate our Buy rating on Micron and maintain our price target of $95.00, above its historical average given the DRAM upturn and continued upside." "We are initiating coverage of Duolingo with a Buy rating and $222 price target (12x 2025 revenues)." Citi reiterates Nvidia as a top pick Citi said it's staying long shares of Nvidia.

Persons: Morgan Stanley, Rivian, Snowflake, Berenberg, Eli Lilly, Unilever, Edward Jones, Goldman Sachs, Piper Sandler, Piper, Datadog, Yuka Broderick, Janney, Argus, Wells, VZIO, MGY, Bernstein, it's, Evercore, Davidson Organizations: Citi, US pharma, Staples, Fractyl Health, Investor Relations, Strategic Finance, American Eagle Citi, Watch, Micron, UBS, Netflix, SUN, Kroger, Industry, Deutsche Bank, Deutsche, Seaport, Bank of America, Gas, Semiconductors, Nvidia, AMD, Seagate, Bank of, underperform Bank of America, JPMorgan, Comerica, CMA

☆ Calls of the Day: Some bullish calls on Netflix, Eli Lilly, General Electric and Snowflake
▼ + stars: | 2024-02-27 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Some bullish calls on Netflix, Eli Lilly, General Electric and SnowflakeThe Investment Committee debates how to trade these names: Netflix, Eli Lilly, General Electric and Snowflake.

Persons: Eli Lilly Organizations: Netflix, Electric

☆ Cost of sickle cell therapies correction
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

Eli Lilly is not suing the Biden administration over the Inflation Reduction Act. An earlier version of this story misstated that.

Persons: Eli Lilly Organizations: Biden

☆ Cramer names contenders for the next company to hit $1 trillion market cap
▼ + stars: | 2024-02-26 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

In the wake of Nvidia 's rapid ascension, CNBC's Jim Cramer on Monday picked companies he thinks could have a chance at breaking $1 trillion in market capitalization. Valued at a little more than $730 billion according to FactSet, drug maker Eli Lilly is Cramer's top contender. At $905 billion, Berkshire Hathaway comes in first and Tesla , which is worth a little more than $611 billion, comes in third, according to FactSet. Broadcom , which is currently worth about $606 billion according to FactSet, has potential because of its enterprising CEO Hock Tan, who Cramer said is adept at making acquisitions. "If that's the case, Nvidia might need to crack the $5 trillion mark before Broadcom crosses the $1 trillion threshold."

Persons: CNBC's Jim Cramer, they're, Eli Lilly, Berkshire Hathaway, Cramer, Warren, Tesla, it's, Hock Tan Organizations: Nvidia, Nvidia —, Broadcom Locations: Berkshire

☆ Eli Lilly could be the next stock to cross $1 trillion, says Jim Cramer
▼ + stars: | 2024-02-26 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly could be the next stock to cross $1 trillion, says Jim Cramer'Mad Money' host Jim Cramer looks at the current class of $1 trillion stocks and looks at what stocks could be poised to join the group.

Persons: Eli Lilly, Jim Cramer

☆ Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared HolzJared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.

Persons: Eli Lilly, Mizuho's Jared Holz Jared Holz Organizations: Novo Nordisk, Zealand Pharma Locations: Mizuho

☆ Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results
▼ + stars: | 2024-02-26 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. Shares of Denmark's Zealand Pharma rocketed higher, after the company posted strong results from a trial of a liver disease treatment that has been touted as a potential competitor in the booming weight-loss drug market. The drug has "demonstrated efficacy" in people with obesity and is currently undergoing five Phase-3 trials in a clinical program for people who are overweight or obese. Analysts latched onto the drug's possible efficacity in obesity research following the latest test results, which indicated the safety of the top dosage used in that trial. Several other firms, including Eli Lilly, Roche and AstraZeneca, also seek to compete in the sector.

Persons: Ozempic, Eli Lilly, Roche Organizations: Novo Nordisk, pharma, Denmark's Zealand Pharma, U.S . Food, Drug Administration, Zealand Pharma, Nordisk, AstraZeneca Locations: Hillerod, Denmark, U.S, London, Danish

☆ After Walmart's stock split, Jim Cramer says this chipmaker should be next
▼ + stars: | 2024-02-26 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Walmart : The Arkansas-based retail giant's 3-for-1 stock split went into effect Monday, and Jim Cramer said he'd like to see other companies consider taking similar moves. "This is something that [CEO] Doug McMillon said that [founder] Sam Walton liked because people don't like partial stock. I think that companies like Broadcom should be listening to that, and they should be splitting," Cramer said. "They gave you a really long-term view, and it was very positive," Cramer said.

Persons: Jim Cramer's, Jim Cramer, Cramer, Doug McMillon, Sam Walton, Berkshire Hathaway, Warren Buffett's, there's, Buffett, it's, Boehringer Ingelheim, Eli Lilly, — Organizations: CNBC, Club, Walmart, Broadcom, Cramer's Charitable Trust, Berkshire, Zealand Pharma Locations: Arkansas, Cramer's, Arbor , Michigan, Danish

☆ Here's how I see the Fed's rate-cut dilemma playing out — and 5 more themes for 2024
▼ + stars: | 2024-02-25 | by ( Jim Cramer | ) www.cnbc.com time to read: +7 min

Here's why: The conversion from three or four cuts to two to one to no cuts won't happen overnight. It won't be a headlong rush out of the stock market. As long as enough people think rate cuts are going to occur, there won't be torrent of money going to the sidelines. What else could influence our thinking for 2024 besides this rate-cut dilemma? As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Nixon, Goldwater, John Ellis, Steve Schwarzman, Blackstone, There's, we're, It's, Estee Lauder, Eaton, Ingersoll Rand, Nucor, Eli Lilly, —, Zepbound, aren't, Jim Cramer, Jim Organizations: CNBC, Club, Fed, Federal Reserve, U.S, Army, U.S . Army, Republican, Federal Trade Commission, Microsoft, Activision, Wynn Resorts, Apple, Palo Alto Networks, Nvidia, GOP, That's, Caterpillar, it's Novo Nordisk, Jim Cramer's Charitable Locations: Vietnam, Wisconsin , Michigan, Pennsylvania, North Carolina , Georgia, Arizona, Nevada, China

☆ Elon Musk's problems keep piling up as Tesla's value slides $188 billion this year
▼ + stars: | 2024-02-24 | by ( George Glover | ) www.businessinsider.com time to read: +6 min

The world's richest person has faced problems at Tesla, SpaceX and X, ranging from a tanking Tesla valuation to an X advertiser exodus. Tesla's stock slide has erased about $188 billion from its valuation this year, according to Business Insider's calculations. The stock closed at just under $192, leaving it worth just over $600 billion at the close of trading Friday. Before you start feeling too sorry for Musk, though, he's still worth $208 billion. Justin Sullivan/Getty ImagesDelaware pay rulingTo add insult to injury, a Delaware judge also ruled against Musk's $55 billion Tesla pay package last month.

Persons: —, Elon Musk, Tesla, Seth Goldstein, Morningstar, Roth, Craig Irwin, Warren Buffett's Berkshire Hathaway, Eli Lilly, he's, He's, Elon, Justin Sullivan, Musk, rkbH7mKNw2, Fidelity, Axios, Starlink, Russia's Organizations: Service, Elon, SpaceX, Business, Big Tech, Microsoft, Apple, Nvidia, Meta, Tesla, EV, Bloomberg, Wall, Getty Images Delaware, Musk's, Lone Star, Twitter, Insider Intelligence, X Locations: Delaware, Tesla, Texas, Ukrainian, Chernihiv, Ukraine, Kyiv, Houston

Search resuls for: "lilly"

25 mentions found